Disulfiram + Copper: The Alcoholism Drug That Triggers Cuproptosis in Cancer

The Bottom Line

Disulfiram (Antabuse) is a 70-year-old alcoholism drug that, when combined with copper, triggers a newly discovered form of cell death called cuproptosis, targeting cancer stem cells that resist conventional therapy. A 2023 randomized clinical trial published in JAMA Network Open tested disulfiram + copper alongside chemotherapy in recurrent glioblastoma. While the trial didn't meet its primary endpoint of overall survival, it established safety and showed biological activity, and subgroup analyses suggested benefit in specific patient populations.

The cuproptosis mechanism, formally described in Science in 2022, has generated enormous research interest. Disulfiram is the most clinically advanced compound exploiting this pathway. At roughly $0.30/day for a generic drug with decades of safety data, it represents one of the most cost-effective repurposed cancer candidates.

How It Works: Cuproptosis

Cuproptosis is a form of cell death triggered by excess intracellular copper. It was formally defined in a landmark 2022 Science paper and is distinct from apoptosis, necrosis, and ferroptosis. The mechanism:

• Disulfiram chelates copper in the body, forming a complex called CuET (copper diethyldithiocarbamate)
• CuET accumulates in cancer cells and delivers copper directly to mitochondria
• Excess mitochondrial copper disrupts the TCA (Krebs) cycle by binding to lipoylated proteins
• This triggers cuproptosis: a copper-specific death pathway that cancer cells cannot easily escape
• Cancer stem cells are particularly vulnerable because they have high ALDH (aldehyde dehydrogenase) activity, which disulfiram also inhibits

The JAMA Trial (2023)

• Design: Randomized, double-blind, placebo-controlled Phase II/III
• Patients: Recurrent glioblastoma (the deadliest brain tumor)
• Treatment: Disulfiram 400mg daily + copper gluconate 2.5mg vs. placebo, both arms receiving alkylating chemotherapy
• Primary endpoint: Overall survival. Not statistically significant in the intent-to-treat population
• Key finding: Safe and well-tolerated. Biological activity confirmed. Subgroup analyses suggested potential benefit in MGMT-unmethylated tumors
• Published: JAMA Network Open 2023

The trial didn't "prove" disulfiram works for GBM, but it didn't rule it out either. The subgroup signal and the safety profile support further investigation, particularly in combination strategies.

Broader Cancer Evidence

• Cancer stem cell targeting: British Journal of Cancer (2012) showed disulfiram/copper is cytotoxic to glioblastoma cancer stem cells and ALDH-positive populations
• Breast cancer: Preclinical activity against TNBC via NF-κB suppression and ALDH inhibition
• Pancreatic cancer: In vitro and in vivo activity, combination synergy with gemcitabine
• Liver cancer: Cuproptosis pathway particularly relevant due to copper accumulation in hepatocytes
• Multiple myeloma: Proteasome inhibition via CuET, synergy with bortezomib

Protocol (From Clinical Trials)

• Disulfiram: 250-500mg daily orally (standard alcoholism dose)
• Copper: 2-2.5mg copper gluconate daily (available over the counter)
• Timing: Take together. The copper is essential for the anticancer mechanism.
• Critical rule: Absolutely no alcohol. Disulfiram + alcohol causes severe nausea, vomiting, and potentially dangerous cardiovascular reactions. This is not optional.
• Cost: ~$10/month (disulfiram) + ~$5/month (copper supplement)

Safety

Disulfiram has been FDA-approved since 1951. Decades of safety data exist:

• Generally well-tolerated when alcohol is avoided
• Hepatotoxicity is rare but reported (monitor liver function)
• Peripheral neuropathy at high doses (similar to DCA)
• Drowsiness and metallic taste are common but mild
• Drug interactions: avoid metronidazole, isoniazid, and certain anticoagulants

Our Assessment

Disulfiram + copper is one of the most scientifically elegant repurposed cancer candidates. The cuproptosis mechanism is novel, the cancer stem cell targeting is unique among repurposed drugs, and the JAMA trial confirmed safety. The main limitation is that the GBM trial didn't show a clear survival benefit in the overall population. But at $15/month for a combination with known safety, potential upside, and minimal downside, it's a reasonable adjunct to discuss with an oncologist, particularly for cancers where ALDH-positive stem cells drive resistance.

Sources

• JAMA Network Open 2023: Disulfiram + copper in recurrent glioblastoma RCT jamanetwork.com
• Science 2022: Discovery of cuproptosis as a distinct cell death mechanism
• Nature Signal Transduction 2025: "Molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer" nature.com
• Br J Cancer 2012;107(9):1488-97: Disulfiram/copper cytotoxicity in glioblastoma stem cells
• Cancer Communications 2025: "Cuproplasia and cuproptosis, two sides of the coin" wiley.com

Related Research

• DCA: Reversing the Warburg Effect (Grade C)
• Mebendazole: The $5 Cancer Drug (Grade B)
• High-Dose IV Vitamin C (Grade A)
• The Anti-Cancer Protocol